

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2025 (24.07.2025)



(10) International Publication Number
WO 2025/155251 A1

(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 21/00 (2006.01)

(21) International Application Number:

PCT/SG2025/050042

(22) International Filing Date:

17 January 2025 (17.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202400151U 17 January 2024 (17.01.2024) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North, Singapore, Singapore 138632 (SG).

(72) Inventors: **STEWART, Colin Lawson**; c/o A*STAR Skin Research Labs (ASRL), 8A Biomedical Grove, Singapore 138648 (SG). **ZHANG, Jinqiu**; c/o A*STAR Skin Research Labs (ASRL), 8A Biomedical Grove, Singapore 138648 (SG). **WONG, Xianrong**; c/o A*STAR Skin Research Labs (ASRL), 8A Biomedical Grove, Singapore 138648 (SG).

(74) Agent: **DAVIES COLLISON CAVE ASIA PTE. LTD.**; 10 Collyer Quay, #07-01 Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF TREATING DYSTROPHINOPATHIES




Figure 2D

(57) Abstract: Provided herein are methods of treating dystrophinopathies and associated conditions using LING complex inhibitors. In one embodiment, the dystrophinopathy is selected from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and DMD-associated dilated cardiomyopathy (DCM). In another embodiment, the associated condition is a myopathy and/or muscular dystrophy. In a further embodiment, the LING complex inhibitor is a dominant negative SUN1 (DNSUN1) polypeptide.

WO 2025/155251 A1